Digestive Care, Inc. (DCI) and its marketing partner to support the U.S. cystic fibrosis community, Chiesi, today announced U.S. Food and Drug Administration (FDA) approval of PERTZYE® (pancrelipase) in a 24,000 USP lipase units capsule. The newly available dosing strength may allow for consumption of fewer capsules to reach the needed weight-based dose. More: http://mwne.ws/2tyAapF